Get a glimpse into our company and investor data—powered by the PitchBook Platform
Series BLATEST DEAL TYPE
$21MLATEST DEAL AMOUNT
Developer and manufacturer of a line of immunologic scoring tests designed to investigate the immune response within the tumor environment. The company's immune-based diagnostics services and products are developed using a proprietary set of Immune biomarkers, advanced image analysis technologies to precisely measure the immune reaction in and around the tumor, enabling clinicians to determine the degree of severity of the patient's disease and to predict response to treatment.